Get the Stockscreener App
1.24
5.08%
0.06
After Hours:
1.27
0.03
+2.42%
Enlivex Therapeutics Ltd stock is traded at $1.24, with a volume of 138.28K.
It is up +5.08% in the last 24 hours and up +27.05% over the past month.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
See More
Previous Close:
$1.18
Open:
$1.19
24h Volume:
138.28K
Relative Volume:
0.60
Market Cap:
$27.27M
Revenue:
-
Net Income/Loss:
$-22.29M
P/E Ratio:
-0.8493
EPS:
-1.46
Net Cash Flow:
$-17.12M
1W Performance:
+3.33%
1M Performance:
+27.05%
6M Performance:
-6.28%
1Y Performance:
-36.57%
1-Day Range:
$1.16
$1.25
1-Week Range:
$1.13
$1.25
52-Week Range:
$0.8101
$4.59
Enlivex Therapeutics Ltd Stock (ENLV) Company Profile
Name
Enlivex Therapeutics Ltd
Sector
Industry
Phone
-
Address
-
Compare ENLV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENLV
Enlivex Therapeutics Ltd
|
1.24 | 27.27M | 0 | -22.29M | -17.12M | -1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Enlivex Therapeutics Ltd Stock (ENLV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-02-21 | Reiterated | H.C. Wainwright | Buy |
Enlivex Therapeutics Ltd Stock (ENLV) Latest News
Enlivex gains Israeli regulatory approval to commence TMJ osteoarthritis trial - Yahoo Finance
Enlivex Receives Regulatory Authorization for the Initiation of A Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - Marketscreener.com
Enlivex Receives Regulatory Authorization for the Initiation of a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis - The Manila Times
Enlivex Therapeutics Advances Allocetra Program with New Phase I Trial for TMJ Osteoarthritis Treatment - StockTitan
Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis - The Manila Times
Enlivex's Allocetra Trial Shows 50% Pain Reduction in Knee Osteoarthritis Study - StockTitan
Enlivex Therapeutics Faces Financial Challenges Amid Losses - TipRanks
Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3 - AccessWire
Enlivex to Showcase Promising Allocetra™ Cell Therapy Data in Exclusive Investor Webinar | ENLV Stock News - StockTitan
Enlivex Therapeutics to Invest in Bitcoin as Part of Cash Management Strategy - Binance
Enlivex Therapeutics : Adopts Bitcoin Treasury Reserve Strategy Form 6 K - Marketscreener.com
Enlivex Therapeutics : X Adopts Bitcoin Treasury Reserve Strateg - Marketscreener.com
Enlivex Adopts Bitcoin Treasury Reserve Strategy - GlobeNewswire
Enlivex Therapeutics to Buy Up to $1M in Bitcoin as Treasury Reserve Asset | ENLV Stock News - StockTitan
Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Sees Significant Growth in Short Interest - Defense World
Armistice Capital, LLC Expands Stake in Enlivex Therapeutics Ltd - GuruFocus.com
Enlivex Announces the Dosing of the First Patient in a - GlobeNewswire
Enlivex Launches Phase I Trial for Novel Psoriatic Arthritis Treatment Allocetra™ | ENLV Stock News - StockTitan
Enlivex stock hits 52-week low at $1.15 amid market challenges - Investing.com Canada
Enlivex Announces the Enrollment and Dosing of the First 10 - GlobeNewswire
Enlivex's Allocetra Advances: Phase II Trial Launches for Knee Osteoarthritis Treatment | ENLV Stock News - StockTitan
Enlivex Announces the Enrollment and Dosing of the First 10 Patient in the Randomized Phase II Stage of its Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis - Yahoo Finance
Enlivex Therapeutics (ENLV) Upgraded to Strong Buy: Here's What You Should Know - MSN
Enlivex Therapeutics Reschedules Annual Shareholders Meeting - TipRanks
Enlivex Receives Notice of Allowance for Japanese Patent - GlobeNewswire
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the Use of Allocetra™ in Patients with Osteoarthritis - StockTitan
New Strong Buy Stocks for October 23rd - MSN
New Strong Buy Stocks For October 23rd - Barchart
Enlivex stock moves forward as Danish agency approves Phase 2 for knee OA By Investing.com - Investing.com South Africa
Enlivex stock moves forward as Danish agency approves Phase 2 for knee OA - Investing.com Australia
EF Hutton maintains price target on Enlivex after trial advancement By Investing.com - Investing.com Australia
Enlivex Advances Knee Osteoarthritis Treatment Trial - TipRanks
Enlivex Receives Authorization from the Danish Medicines - GlobeNewswire
Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis - StockTitan
ENLVEnlivex Therapeutics Ltd. Ordinary Shares Latest Stock News & Market Updates - StockTitan
Enlivex Progresses to Phase II for Knee Arthritis Treatment - TipRanks
Enlivex Announces Positive DSMB Recommendation to Initiate - GlobeNewswire
Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis - StockTitan
India News | ⚡Kolkata-Based Company Ellenbarrie Industrial Gases Files IPO Papers - LatestLY
Enliven Therapeutics director sells $28,458 in company stock By Investing.com - Investing.com Canada
Enliven Therapeutics Announces Details Regarding the - GlobeNewswire
Ellenbarrie Industrial Gases Files For IPO To Raise Rs 400 Crore - NDTV Profit
Enmy & The Cure - RAMzine
ENLV’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - The InvestChronicle
Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation - Simply Wall St
All You Need to Know About Enlivex Therapeutics (ENLV) Rating Upgrade to Buy - MSN
Enlivex Announces 2024 Shareholder Meeting - TipRanks
Enlivex Therapeutics (NASDAQ:ENLV) Given Buy Rating at HC Wainwright - Defense World
Enlivex stock poised for growth with key trial readouts by 2025, says H.C. Wainwright - Investing.com India
Enlivex Therapeutics Financials Indicate Net Loss - TipRanks
Enlivex Therapeutics Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
Enlivex Therapeutics Ltd Stock (ENLV) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):